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patients with visible hematuria, as visible hematuria in anticoagulated patients can be distressing,
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ns.org/licenses/by-nc-nd/4.0/)Hematuria is responsible for up to a third of emer-gency urological referrals, and up to two-thirds ofadmitted patients with hematuria are reported to
be on anticoagulation.1-3 Visible hematuria can be difﬁcult
to control and life-threatening, particularly in anticoagu-
lated patients.4,5 A recent large retrospective cohort study
from Canada included older adults and demonstrated
higher rates of hematuria-related complications with than
without antithrombotic medications.5 Furthermore, hema-
turia can be distressing for the patient and consequently
might lead to poor compliance with the anticoagulant
therapy, an increased risk of stroke and even death.6−8
The most recent review on visible hematuria and oral
anticoagulant medication suggested that there is an
increased risk of potentially life-threatening major hema-
turia in patients on therapy with direct oral anticoagulants
(DOACs).4 However, this conclusion was based on the
pooled analysis of only 33 DOAC patients in more than1https://doi.org/10.1016/j.urology.2019.06.004
0090-4295
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175,000 patients on antithrombotic therapy. Although
there have been extensive studies on the classical vitamin
K antagonist (VKA) warfarin, little is known about visible
hematuria in patients on the new DOACs. This is an
important omission, as current guidelines on anticoagulant
treatment in venous thromboembolism and atrial ﬁbrilla-
tion support the use of DOACs rather than VKA, so that
the prevalence of DOACs in emergency admissions has
rapidly increased.9-11
The present study therefore investigated the length of
hospital stay (LOS) and hospital admission rate as primary
outcomes in visible hematuria patients on DOACs − in
comparison to patients on (1) VKA and (2) without any
anticoagulant medication. The secondary outcomes were
in-hospital mortality, length of emergency department
(ED) stay, and admissions to the intensive care unit (ICU).METHODS
Study Design and Setting
This retrospective cohort study was set in the adult ED of Bern
University Hospital (Inselspital), Switzerland, a self-contained,
interdisciplinary department treating patients aged 18 years and
older.
Inclusion Criteria
All patients were included who were admitted from January 1,
2013 to December 31, 2016 to our ED with a diagnosis of visible
hematuria.
Exclusion Criteria
The following exclusion criteria were used:
 No signs of visible hematuria, eg, micro hematuria,
 Visible hematuria in the history, but not current,
 Elective, clinical control after emergency consultation,
 Nonspeciﬁed hematuria or insufﬁcient information for inclusion
ie, missing diagnosis.
For the sake of legibility, the expression “visible hematuria” is
replaced throughout by “hematuria”.
Study Outcomes
The primary outcomes were hospitalization rate and length of
stay (LOS), deﬁned as time in hospital. Secondary outcomes
were ICU admission, length of ED stay (deﬁned as time in ED)
as well as in-hospital mortality.
Data Collection and Extraction
A full text search in the medical database of the ED (E.care, Turnh-
out, Belgium) was performed for the keywords “hematuria” (and
spelling variants) from January 1, 2013 to December 31, 2016. The
patient histories and diagnoses were analyzed in full text to test the
eligibility criteria and to determine study inclusion.
Patient characteristics (age, gender), characteristics of patient
ED interaction (admission type and triage category) and investi-
gated study outcomes were extracted from the medical database.
Triage in our ED is made by registered nurses using the Swiss triage
scale.12 Furthermore, laboratory results from the ED evaluation
were collected (ie, creatinine, international normalized ratio [INR],
hemoglobin [Hb], and platelets).2The following medical data were extracted manually from the
full text ED records: indication for oral anticoagulation, addi-
tional therapy with platelet aggregation inhibitors, type of plate-
let aggregation inhibitor therapy, abdominal trauma, current
abdominal pain, pre-existing structural urological conditions
(nephrostomy, ileum conduit, and permanent bladder catheter),
and previous (<7 d) invasive urological intervention (eg, recent
bladder, renal or prostate surgery). To classify the comorbidity of
the included patients, the Charlson Comorbidity Index was
determined,13 with full-text analysis of the diagnosis (including
diabetes mellitus, liver disease, malignancy, AIDS, chronic kid-
ney disease, chronic heart failure, COPD, peripheral vascular
disease, dementia, peptic ulcer disease, connective tissue disease,
cerebrovascular disease, hemiplegia, infarction as well as age).
Additionally, the characteristics of hematuria were described,
including recurrent bleeding, dysuria, associated urogenital
infection, pre-existing urological tumor (including bladder, pros-
tate, or renal malignancy), start of hematuria, urine blood clot,
bladder tamponade, urinary retention, treatment (observational,
lavage catheter, or emergency operation), and blood transfusion.
The deﬁnition of a “major hematuria” is inconsistent in the
urological literature.4 In order to give an impression of the
extent and severity of hematuria, 2 deﬁnitions of severe hematu-
ria used in the literature are presented in this manuscript: (1)
“major hematuria” deﬁned by the presence of bladder tamponade
or placement of a lavage catheter, (2) “relevant hematuria”
deﬁned by the need of hospital admission or the need of blood
transfusion.
Exposure
In order to determine anticoagulation status on arrival, the iden-
tiﬁed full text records were manually screened for VKA medica-
tions − “acenocoumarol”, “phenprocoumon”, or “warfarin” − as
well as DOAC medication − “apixaban”, “dabigatran”, “edoxa-
ban”, or “rivaroxaban”. The included patients with hematuria
were grouped by anticoagulant status (DOAC, VKA, and no
anticoagulation).
Data Analysis
All statistical analyses were performed in Stata 13.1 (StataCorp,
The College Station, TX) and statistical signiﬁcance was deﬁned
as a P <.05. For descriptive analysis, proportion was accompa-
nied by the total number in the category and continuous varia-
bles as medians with interquartile range (IQR). DOAC patients
were compared to VKA patients or to patients without anticoag-
ulant medication, with respect to different variables, using the
Mann Whitney U or Fisher's exact tests, as applicable.
Potential confounders for multivariable modeling were identi-
ﬁed by univariable testing. All identiﬁed confounders (with at
least very weak evidence, deﬁned as P <.2,14 for an univariable
association with type of anticoagulation using Kruskal Wallis
respectively Fisher’s exact tests,) were included in the multivari-
able model. Multivariable associations between study outcomes
and the type of anticoagulation were analyzed by models of linear
regression (continuous outcomes) or logistic regression (binary
outcomes; odds ratios as a measure of strength of association),
including potential cofounders. In order to allow multivariable
linear regression, non-normally distributed data were log trans-
formed. We therefore present the exponentiated coefﬁcients of
the regression analysis, as these correspond to the geometric mean
(GM) ratio of the nonlog transformed values.
To test the robustness of our primary ﬁndings, we conducted
sensitivity analysis, which varied the included variables in ourUROLOGY 00 (00), 2019
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multivariable model by (1) including all potential confounders,
(2) removing covariables that showed less than weak evidence
(P >.1) to obtain the ﬁnal model (backward selection), and (3)
excluding all patients without anticoagulation in the ﬁnal
multivariable model.
The mechanisms of hematuria may be different for patients
with trauma or urogenital infection compared to patients with
chronic conditions or with hematuria of unknown mechanism.
Subgroup analysis excluding trauma and urogenital infections
was therefore performed.Ethics
The need for informed consent was waived by the ethics com-
mittee of Canton Bern, Switzerland, as the patient data were
anonymous and part of routine patient care. The study is regis-
tered with the responsible ethics committee under the number
073/2015.RESULTS
Baseline Characteristics
The key word database search of all 131,229 patients admitted
over the 4 years study period identiﬁed 3,229 ED admissions.
Full text screening of the medical reports excluded 2,418 ED
admissions, mostly due to missing signs of hematuria (n = 1,762)
(eg, diagnosis of micro hematuria) or solely historical hematuria
(n = 576). Finally, 811 (100%) patients could be included in the
primary analysis. No included patient had more than one consul-
tation in the study period with hematuria. Fifty-three (53, 6.5%)
patients were on DOAC therapy (47 [88.7%] rivaroxaban, 5
[9.4%] apixaban, 1 (1.9%) dabigatran) and 85 (10.5%) on VKA
therapy (82 [96.5%] phenprocoumon, 2 [2.4%] acenocoumarol,
1 [1.2%] warfarin). The median INR 2.4 (IQR 1.8-3.2) was in
the therapeutic range in the VKA group.
Platelet-aggregation-inhibitor therapy was documented in
157 patients (19.5%). The predominant type of platelet-aggre-
gation-inhibitor therapy was acetylsalicylate acid in all groups
(for overview of all baseline characteristics, see Table 1).
Relevant hematuria was found signiﬁcantly more often
(P = .011) in anticoagulated patients (DOAC: 52.8%, VKA:
64.7%) than in patients without anticoagulation (no anticoagu-
lation: 34.5%; for overview of all hematuria characteristics).Identification of Potential Confounders
All potential confounders except for urolithiasis (P = .942),
abdominal pain (P = .295), and therapy with platelet aggrega-
tion inhibitors (P = .650) showed at least very weak evidence
(P <.2) for a difference between the three study groups and were
therefore included in the multivariable model. The associations
of all potential confounders with the type of anticoagulant are
shown in Table 2.Association of Clinical Outcomes and Type of
Anticoagulant
In univariable analysis, the primary outcomes of hospitalization
rate and length of hospitalization did not exhibit a signiﬁcant
association with the type of anticoagulant (VKA vs DOAC)
(P = .166 and P = .071, respectively). There was a small number
of deaths in all study groups without signiﬁcant difference in
mortality between the groups (P = .456). In-hospital mortality
was therefore removed from the multivariable analysis. AllUROLOGY 00 (00), 2019univariable associations of the clinical outcomes with the type of
anticoagulant are shown in Table 3.
After adjustment for associations with the identiﬁed con-
founders in the multivariable analysis, positive associations were
identiﬁed between hospitalization rate (odds ratio [OR] 2.3;
95% conﬁdence interval [CI]: 1.1, 4.9; P = .027) and LOS (GM
2.2 [95% CI: 1.3, 4.0], P = .006) and the type of anticoagulant
(VKA compared to DOAC) (Table 4). The number of urologi-
cal interventions performed, were not signiﬁcantly different in
both groups (DOAC 13 [46.4%] vs 21 [38.2%], P = .275).
The most common reasons for hematuria reported in hospital-
ized patients in the DOAC and VKA group were unspeciﬁc
OAK-related bleeding (DOAC 5 [17.9%] vs VKA 19 [34.5%]),
neoplasm (DOAC 9 [32.1%] vs 9 16.4%]), and infection
(DOAC 3 [10.7%] vs 12 [21.8%]) without signiﬁcant difference
between the groups (P = .306).
No signiﬁcant associations (P = .977 and P = .998) were found
between the primary outcomes and the group with no anticoagu-
lation compared to DOAC.
The secondary outcomes did not exhibit any signiﬁcant asso-
ciation with the anticoagulation groups in confounder-adjusted
multivariable analysis.
Sensitivity Analysis
Analysis of sensitivity in confounder-adjusted multivariable
analysis showed that the signiﬁcant positive associations
between hospitalization and LOS and the type of anticoagu-
lant (VKA compared to DOAC) were robust (presented as
Supplementary Table 1-3)
Confounder-adjusted Multivariable Subgroup Analysis
After Exclusion of Trauma and Urogenital Infections
After exclusion of all patients with a documented urogenital
infection or trauma, there remained a subgroup including 43
patients with DOAC, 64 patients with VKA anticoagulation,
and 370 patients with no anticoagulation. Restriction of the
analysis to these patients enhanced the previously identiﬁed
positive associations between hospitalization rate (OR 2.8
[95%: CI 1.2, 6.6], P = .017) and LOS (GM 2.7 [95% CI: 1.4;
5.3], P = .004) and the type of anticoagulant (VKA compared
to DOAC) (Supplementary Table 4).DISCUSSION
In confounder-adjusted multivariable testing, our study
found fewer hospital admissions as well as shorter LOS in
hematuria patients seen in the ED on DOAC than on
VKA. The length of stay in ED, ICU admissions as well as
in-hospital mortality − the secondary outcomes − did not
differ signiﬁcantly between the DOAC and VKA groups.
Primary Outcomes: Hospitalization Rate and LOS
In confounder-adjusted multivariable modeling, our study
identiﬁed a nearly three-fold increase in the odds for hos-
pitalization and a similar increase in LOS for patients on
VKA therapy compared to patients on DOAC. As in-hos-
pital patient treatment is a relevant cost-factor compared
to outpatient medicine, these ﬁndings may not only be of
beneﬁt for the treatment of the individual patient but can
also contribute to a reduction in the ﬁnancial burden on
the healthcare system from bleeding complications.3
Table 1. Baseline and hematuria characteristics of the study cohort according to type of anticoagulant
Characteristics DOAC VKA P*
No Anticoagulant
Therapy P*
Patient data
N 53 (100.0) 85 (100.0) — 673 (100.0) —
Age (years) 77 (65-85) 73 (66-80) .175 52 (33-71) <.001
Admission
Walk-in 24 (45.3) 43 (50.6) 471 (70.0)
GP referral 7 (13.2) 17 (20.0) 62 (9.2)
Out-patient 7 (13.2) 14 (16.5) 41 (6.1)
Secondary transfer 15 (28.3) 11 (12.9) .159 99 (14.7) .002
Triage category 3 (2-3) 3 (2-3) .673 3 (3-3) <.001
Indication for anticoagulant therapy
Atrial fibrillation 18 (33.3) 35 (40.7) — —
Thromboembolic event 18 (33.3) 22 (25.6) — —
Mechanic heart-valve 1 (1.9) 17 (19.8) — —
Post-surgery 1 (1.9) 0 (0) — —
Other 10 (18.6) 6 (7.0) — —
Not documented or unknown 6 (11.1) 6 (7) .003 — —
Additional platelet-aggregation-inhibitor therapy#
Acetylsalicylate acid 10 (18.9) 12 (14.0) 110 (16.3)
Clopidogrel 2 (3.8) 3 (3.5) 20 (3.0)
Prasugrel 0 (0.0) 0 (0.0) 1 (0.2)
Ticagrelor 0 (0.0) 0 (0.0) 1 (0.2)
None 41 (77.4) 71 (83.5) .621 541 (80.2) .741
Laboratory data
Creatinine (mmol/L)+ 100 (85-125) 99 (80-137) .823 82 (68-107) .002
INR+ 1.1 (0.9-1.3) 2.4 (1.8-3.2) <.001 0.9 (0.9-0.9) <.001
Hemoglobin (g/L)+ 121 (103-139) 123 (106-143) .302 133 (120-145) .002
Platelets (G/l) 226 (190-280) 214 (159-291) .425 233 (190-286) .661
Hematuria characteristics
Recurrent bleeding 20 (37.7) 25 (29.4) .353 145 (21.6) .010
Visible hematuria start [d]+ 1 (0-3) 1 (0-4) .656 0 (0-1) .053
Blood clot 6 (11.3) 20 (23.5) .116 131 (19.5) .200
Tamponade 6 (11.3) 9 (10.6) 1.000 78 (11.6) 1.000
Urinary retention 7 (13.2) 12 (14.1) 1.000 104 (15.5) .843
Relevant hematuria 28 (52.8) 55 (64.7) .211 232 (34.5) .011
Major hematuria 17 (32.1) 25 (29.4) .849 150 (22.3) 0.126
Dysuria 6 (11.3) 25 (29.4) .020 291 (43.2) <.001
Treatment
Observational (wait & see) 36 (67.9) 63 (74.1) 537 (79.8)
Lavage catheter 16 (30.2) 20 (23.5) 127 (18.9)
Surgical (emergency operation) 1 (1.9) 2 (2.4) .747 9 (1.3) .089
DOAC, direct oral anticoagulant; N, number; VKA, Vitamin K antagonists.
Median (interquartile range) or number (percentage) as appropriate.
*Mann Whitney U or Fisher’s exact test of the comparison between group of columns left of p value with DOAC group as applicable.
# Any patient may be on more than one medication.
+Missing values in percent (DOAC, VKA, no anticoagulation): Creatinine (9.4%, 9.4%, 24.7%); INR (9.4%, 9.4%, 28.7%); Hemoglobin
(7.6%, 10.6%, 24.1%), Visible hematuria start (11.3%, 15.3%, 8.0%).
ARTICLE IN PRESSThe ﬁndings were (1) robust in subgroup analysis per-
formed to exclude the inﬂuence of the potential differences
in mechanism of hematuria in trauma and urological infec-
tions (Supplementary Table 4) and (2) could also be con-
ﬁrmed in multiple sensitivity analyses with variations in
the multivariable modeling (Supplementary Table 1-3). In
addition, we did not ﬁnd a difference in urological proce-
dures between both groups nor in the deﬁnitive cause of
hematuria that may explain this ﬁnding.
One of the reasons contributing to the presented ﬁnding
may be that DOAC have shorter half-lives than VKA and
that stopping DOAC therapy is known to be sufﬁcient in
most bleeding situations.15 In contrast to this, bleeding
events on VKA therapy frequently warrant reversal of4anticoagulant therapy.15 In contrast to this, VKA therapy
must be restarted carefully, often in an in-hospital setting.
This ﬁnding in hematuria patients is consistent with
the shorter LOS and fewer hospital admissions that had
also been demonstrated in our ED population for other
bleeding complications (epistaxis patients) on DOAC
compared to VKA.16 Other factors that may inﬂuence the
risk of bleeding risk in patients on anticoagulant drugs
include problems with medication compliance, variations
in individual anticoagulant effect or acute variations in
renal function that may lead to nontherapeutic DOAC
concentrations. Unfortunately, measurement of DOAC
concentrations is not part of routine ED evaluation and
the time point of the last intake of DOAC is oftenUROLOGY 00 (00), 2019
Table 3. Univariable outcome analysis of patients according to type of anticoagulant
Outcomes DOAC VKA P*
No Anticoagulant
Therapy P*
Primary
Hospitalization rate 28 (52.8) 55 (64.7) .211 232 (34.5) .011
Length of hospital stay, days 1.0 (0.2-4.0) 3.0 (0.2-7.0) .071 1.0 (0.1-3.0) .002
Secondary
Admission ICU 4 (7.6) 9 (10.6) .766 28 (4.2) .283
Length of ED stay, min 251 (198-316) 267 (198-371) .495 206 (142-306) .004
In-hospital death 1 (1.9) 0 (0.0) .384 7 (1.0) .456
DOAC, direct oral anticoagulant; ED, emergency department; ICU, intermediate care unit; VKA, Vitamin K antagonists.
Median (interquartile range) or number (percentage) as appropriate.
*Mann-Whitney U or Fisher’s exact test of the comparison between group of columns left of P value and DOAC group as applicable.
Table 2. Potential confounders of the association type of anticoagulant and length of hospital stay/hospitalization
DOAC VKA P*
No Anticoagulant
Therapy P+
Gender (female) 11 (20.8) 22 (25.9) .543 251 (37.3) .008
Therapy with platelet aggregation inhibitors 12 (22.6) 14 (16.5) .380 132 (19.6) .650
Abdominal trauma 1 (1.9) 1 (1.2) 1.000 49 (7.3) .028
Abdominal pain 22 (41.5) 33 (38.8) .858 317 (45.1) .295
Charlson Comorbidity Index 6 (4-10) 5 (3-7) .019 2 (0-5) <.001
Pre-existing structural urogenital condition 18 (34.0) 18 (21.2) .113 94 (14.0) .001
Urolithiasis 4 (7.6) 8 (9.3) .767 65 (9.7) .942
Previous urological intervention 4 (7.6) 1 (1.2) .072 31 (4.6) .150
Urogenital tumor 39 (73.6) 14 (26.4) .298 76 (11.3) .003
Urogenital infection 9 (17.0) 20 (23.5) .398 258 (38.3) <.001
DOAC, direct oral anticoagulant; N, number; VKA, Vitamin K antagonists.
Median (interquartile range) or number (percentage) as appropriate.
*Mann Whitney U or Fisher’s exact test of the group comparison: DOAC vs VKA.
+ Kruskal Wallis test or Fisher’s exact test of the group comparison: all groups.
ARTICLE IN PRESSunknown. Therefore, we cannot exclude that a subopti-
mal compliance with DOAC therapy contributes to the
results of our study. As compliance is a known major issue
with many medications and skipping only one dose plays
no role in VKA compared to DOAC, further research is
needed on the inclusion of DOAC level measurements in
clinical routine practice.17 In contrast to this, INR meas-
urements are part of routine evaluation and conﬁrmed
therapeutic VKA levels in the majority of our patients.
The combination of DOAC or VKA and inhibitors of
platelet aggregation has been previously found to increase
the risk of hematuria-related complications, including hos-
pital admissions.5 This association could not be replicated
in our population as in our speciﬁc hematuria bleeding pop-
ulation, platelet aggregation inhibitor therapy did not turn
out to be a signiﬁcant confounder. Additional research on
the combination of antithrombotic and DOAC medication
in hematuria patients is warranted. Furthermore, future
research could investigate the possibility of identifying
patients with preconditions that are more vulnerable to
hematuria with different types of anticoagulant.
In the comparison of DOAC with patients without anti-
coagulant medication, in univariable testing, we could dem-
onstrate a signiﬁcant difference between DOAC and no
anticoagulation. In contrast to the comparison of DOAC
and VKA, in multivariable testing, controlled for confound-
ers identiﬁed in our investigation, the comparison of DOAC
with patients without anticoagulant medication failed toUROLOGY 00 (00), 2019demonstrate any signiﬁcant difference for hospitalization
or LOS.
This ﬁnding is inconsistent with the higher odds of hospi-
talization found byWallis et al5 for every anticoagulant med-
ication. Older investigations − dating back to 1994 − found
no association between anticoagulant use and hematuria but
did not include the newer DOAC medications.18 The rea-
son for this ﬁnding cannot be conclusively clariﬁed with our
retrospective study. To investigate, if there might be addi-
tional confounders not included in our study or if the faster
and easier procedure of stopping and restarting DOAC ther-
apy compared to VKA contributes to this ﬁnding, further
prospective research is necessary.Secondary Outcomes: In-hospital Mortality, ICU
Admission and Length of ED Stay
In the light of our main ﬁndings of increased LOS and hos-
pitalization in VKA compared to DOAC patients, it is reas-
suring that (1) no patient died during ED care and only
very few patients died in hospital − without any difference
between the investigated groups, (2) no difference in ICU
admission was found and (3) there were no signiﬁcant dif-
ference in the length of ED stay for different anticoagula-
tion status − probably because the ED treatment was
similar.15 This supports the evidence that implementation
of local emergency guidelines is crucial for the management
of anticoagulant bleeding.15,195
Table 4. Uni- and multivariable analysis for the (A) primary outcomes hospitalization and length of hospital stay and (B) sec-
ondary outcomes length of ED stay and ICU admission and DOAC vs VKA or DOAC vs no anticoagulation.
A)
Hospitalization Odds Ratio (95% CI) P
Univariable
DOAC vs VKA 1.64 (0.81, 3.29) .167
DOAC vs no anticoagulation 0.47 (0.27, 0.82) .008
Multivariable
Group
DOAC 1.0 (base)
VKA 2.33 (1.10, 4.94) .028
No anticoagulation 0.99 (0.53, 1.86) .977
Gender [being female] 0.54 (0.37, 0.79) .002
Abdominal trauma 2.87 (1.54, 5.32) .001
Charlson Comorbidity Index [per point] 1.22 (1.16, 1.29) <.001
Structural urogenital condition 0.68 (0.44, 1.06) .087
Previous urological intervention 0.89 (0.43, 1.89) .771
Urogenital infection 0.61 (0.41, 0.90) .013
Length of Hospital Stay (log transformed) GM Ratio (95% CI)* P
Univariable
DOAC vs VKA 1.77 (0.95, 3.31) .071
DOAC vs no anticoagulation 0.49 (0.28, 0.82) .007
Multivariable
Group
DOAC 1.0 (base)
VKA 2.24 (1.26, 4.00) .006
No anticoagulation 1.00 (0.61, 1.64) .998
Gender [being female] 0.67 (0.51, 0.88) .005
Abdominal trauma 3.20 (0.38, 0.63) <.001
Charlson Comorbidity Index [per point] 1.20 (1.15, 1.25) <.001
Structural urogenital condition 0.68 (0.48, 0.96) .025
Previous urological intervention 0.49 (0.39, 1.24) .219
Urogenital infection 0.67 (0.50, 0.89) .006
B)
Length of ED Stay (log transformed) GM Ratio (95% CI)* P
Univariable
DOAC vs VKA 1.05 (0.89, 1.23) .599
DOAC vs no anticoagulation 0.81 (0.68, 0.94) .007
Multivariable
Group
DOAC 1.0 (base)
VKA 1.07 (0.88, 1.29) .486
No anticoagulation 0.9 (0.76, 1.06) .194
Gender [being female] 0.89 (0.82, 0.98) .014
Abdominal trauma 1.07 (0.91, 1.26) .390
Charlson Comorbidity Index [per point] 1.03 (1.01, 1.04) <.001
Structural urogenital condition 0.87 (0.78, 0.97) .011
Previous urological intervention 0.85 (0.7, 1.02) .084
Urogenital infection 0.87 (0.8, 0.96) .005
ICU Admission Odds Ratio (95% CI) P
Univariable
DOAC vs VKA 1.45 (0.42, 4.97) .554
DOAC vs no anticoagulation 0.53 (0.18, 1.58) .255
Multivariable
Group
DOAC 1.0 (base)
VKA 1.74 (0.49, 6.24) .394
No Anticoagulation 0.53 (0.16, 1.77) .301
Gender [being female] 1.27 (0.57, 2.82) .562
Abdominal trauma 16.20 (6.86, 38.27) <.001
Continued
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Table 4. Continued
ICU Admission Odds Ratio (95% CI) P
Charlson Comorbidity Index [per point] 1.10 (0.98, 1.23) .108
Structural urogenital condition 1.39 (0.59, 3.29) .449
Previous urological intervention# — —
Urogenital infection 0.67 (0.15, 1.23) .114
CI, confidence interval; DOAC, direct oral anticoagulant; ED, emergency department; GM, geometric mean; ICU, intensive care unit.
* All coefficients are expressed as exponentials to correspond to the GM ratio.
# Predicts failure perfectly and was dropped from the analysis together with 36 non used consultations
ARTICLE IN PRESSEmergency physicians should know about the pros and
cons of the different anticoagulant medications in order
to counsel the patient and his/her treating physician as
anticoagulation is frequent in ED patients.
Limitations
As our investigation is limited to ED admissions of one sin-
gle center, the transferability to other patient populations
remains unknown and warrants further investigations.
Documentation bias cannot be completely excluded in
any retrospective investigation, despite careful review of
all included data. Because this is a retrospective study,
missing data cannot be completely avoided despite great
efforts to guarantee the completeness of the data extrac-
tion and to keep the number of missing values as low as
possible. Nevertheless, these biases can be assumed to be
equally distributed between all patients groups and are
therefore most likely not to compromise the conclusion of
this study.
The distribution of the difference DOACs, with rivar-
oxaban being the DOAC with the highest prevalence in
our data, reﬂects the DOAC distribution in our popula-
tion.10 The general prevalence of patients on anticoagula-
tion is also mirrored in group size of anticoagulation vs
no-anticoagulation group.
Further prospective multicenter investigations are rec-
ommended. These should include more patients on differ-
ent DOACs. DOAC levels should be measured, to
evaluate the inﬂuence of possible medication interac-
tions20 or medication compliance as well as the timing of
last medication intake.CONCLUSION
Visible hematuria is associated with a lower risk of hospi-
talization together with shorter LOS in patients on
DOAC compared to patients on VKA therapy. This ﬁnd-
ing may help the clinician to select anticoagulant therapy
for patients at risk for hematuria.
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